The waiting room was quiet in the way only a fertility clinic can be quiet. A couple in their late thirties sat with a folder between them, the kind of folder that holds consent forms, lab slips, and a single sheet of paper they kept turning back to. It was not a medical result. It was an estimate. The bottom line had changed three times since their first consultation, and neither of them could say, with confidence, what the full course of treatment would actually cost.
That scene repeats in clinics across the country every day, and it points to a structural problem in American fertility care: the medicine has advanced faster than the pricing.
A market built on averages that hide the bill
Ask what IVF costs in the United States and the answer usually arrives as a range so wide it is nearly useless. The American Society for Reproductive Medicine has long put a single IVF cycle at roughly $12,000 to $17,000 for the procedure itself, before medication. Add fertility drugs, which commonly run $3,000 to $7,000 per cycle, and a single attempt routinely lands above $20,000. The Centers for Disease Control and Prevention reported more than 390,000 assisted reproductive technology cycles performed in the United States in 2022, with roughly 91,000 live births resulting — a reminder that many families pay for more than one cycle.
Those national figures, however, conceal the variation that matters most to a patient. A clinic in one city may charge $11,000 for a cycle that costs $18,000 two states away. Genetic testing of embryos, known as PGT, can add $3,000 to $6,000. Anesthesia, monitoring, embryo freezing, and storage fees arrive as separate line items, sometimes disclosed late. A 2023 survey of fertility patients by the patient-advocacy group RESOLVE found that cost was among the most common reasons patients delayed or stopped treatment — a finding that should trouble any clinic that measures success only in pregnancy rates.
Age sharpens the stakes. CDC data show live-birth rates per egg retrieval falling steeply as maternal age rises: women under 35 have markedly higher success rates than women over 40, for whom a single cycle succeeds far less often. That means the patients facing the longest odds are also the patients most likely to need multiple cycles — and therefore the most exposed to opaque pricing. A family that budgets for one cycle and needs three has not misplanned. It has been misled by a system that quotes the first step as if it were the whole journey.
What transparency would actually look like
Other corners of healthcare have already been forced toward the light. Since 2021, federal hospital price-transparency rules have required hospitals to publish standard charges, and the No Surprises Act, effective in 2022, limits unexpected out-of-network bills in many emergency and facility settings. Fertility care, much of it paid out of pocket and delivered in freestanding clinics, has largely sat outside those reforms. The result is a market where comparison shopping — routine for a car, a mortgage, or even a knee replacement — remains strangely difficult for a $25,000 medical decision.
Real transparency in fertility would have four parts. First, an all-in cycle price: procedure, monitoring, laboratory work, and anesthesia in one number, with medication shown as a stated range rather than a footnote. Second, success rates reported alongside price, by age band, so a cheaper clinic with far lower success rates cannot hide behind its sticker price. Third, a clear statement of what happens if a cycle is cancelled — how much is refunded, and what carries forward. Fourth, financing terms in plain language: interest rates, total repayment, and what happens if treatment stops early.
Some clinics already do much of this. Shady Grove Fertility, one of the largest networks in the country, publishes program pricing and a shared-risk refund program on its website. Kindbody, a venture-backed fertility company, built its early pitch around published prices and employer partnerships. Their example matters because it refutes the claim that transparency is commercially impossible. Clinics that publish prices have not vanished. They have grown.
The counterargument, stated fairly
Clinic leaders who resist full price publication raise a serious point, and it deserves a direct answer. Fertility treatment is not a commodity. Two patients with the same diagnosis may need different protocols, different drug doses, and different laboratory techniques. A clinic that posts a single flat price, critics argue, risks misleading patients in the other direction — implying a simple product where the medicine is genuinely individual.
That concern is real, but it is an argument for better disclosure, not for none. A restaurant menu does not promise that every diner will spend the same amount, yet it still lists prices. Fertility clinics can publish a base cycle price, a typical medication range, and the common add-ons with their prices, while stating plainly that individual protocols vary. The alternative — no published price at all — does not protect patients from confusion. It guarantees it, and it hands the advantage to the clinics least willing to be compared.
Who pays when prices stay hidden
The costs of opacity fall unevenly. A 2022 analysis by the Kaiser Family Foundation found that only a minority of states require insurers to cover fertility treatment, and mandates vary widely in what they include. That leaves most patients paying out of pocket, drawing on savings, credit cards, or family loans. Surveys by FertilityIQ, a patient-review platform, have repeatedly found that a substantial share of patients spend $30,000 or more across their treatment, with many reporting that final costs exceeded their initial estimates.
The implications
Fertility care sits at the intersection of medicine, finance, and one of life's most consequential decisions. A market that asks families to commit tens of thousands of dollars without a clear price is not merely inconvenient. It distorts who gets care, how much care they get, and when they stop. Lower-income patients delay treatment, and delay itself lowers success rates, compounding the disadvantage.
Clinics can publish all-in prices voluntarily, and the ones that do will earn a trust advantage advertising cannot buy. Employers can require price and outcome reporting as a condition of network participation. Patient groups can standardize the questions every family should ask before a first cycle: What is included? What is not? What does a second cycle cost? What is refunded if we stop?
Back in that waiting room, the couple with the folder eventually got an answer — a revised estimate, higher than the first, lower than they feared. They proceeded. They were fortunate in ways that had little to do with medicine: they had savings, flexible jobs, and the persistence to keep asking. A fairer system would not depend on fortune. It would start with a number, stated plainly, before the first injection. That is not a radical demand. It is the minimum a market this expensive and this personal owes the people who pay for it.
Sources: Sources cited in this article: American Society for Reproductive Medicine cost guidance; Centers for Disease Control and Prevention, 2022 Assisted Reproductive Technology report; RESOLVE patient surveys; Kaiser Family Foundation analysis of state fertility coverage mandates; FertilityIQ patient cost surveys; company materials from Shady Grove Fertility, Kindbody, Progyny, and Carrot Fertility.